Frith J A, McLeod J G, Basten A, Pollard J D, Hammond S R, Williams D B, Crossie P A
Clin Exp Neurol. 1986;22:149-54.
The result of a two year, double blind, controlled trial of Transfer Factor (TF) in the treatment of multiple sclerosis (MS) were reported in 1980. It was demonstrated that TF significantly reduced the rate of progression of the disability but the benefit of therapy was not apparent until 18 months after its commencement. After the completion of the trial, TF treatment was offered to all the trial participants. Forty-five of these people accepted TF as treatment and have been followed for the subsequent three years. The twenty-three people who had received TF during the trial, and continued on TF after the trial, consistently had a slower rate of progression of their MS. Although the twenty-two patients initially on placebo had a significantly faster rate of progression during the trial, this slowed with commencement of TF treatment. After 3 years of TF, the rate of progression of disease was similar to that of the group receiving TF continuously for 5 years. In addition, 470 patients with clinically definite MS are being treated in New South Wales in an open study of TF. The rate of progression of the disease is being monitored by neurological assessments and appears to be similar to that of patients who had received TF in the original trial. The follow-up study of the 1980 TF trial patients and the open study of 470 MS patients confirm the original observation that TF has some effect on slowing the course of MS.
1980年公布了一项为期两年的转移因子（TF）治疗多发性硬化症（MS）的双盲对照试验结果。结果表明，TF显著降低了残疾进展速度，但治疗效果直到开始治疗18个月后才显现出来。试验结束后，向所有试验参与者提供了TF治疗。其中45人接受了TF治疗，并在随后三年中接受随访。在试验期间接受TF治疗且试验后继续接受TF治疗的23人，其MS进展速度始终较慢。尽管最初接受安慰剂治疗的22名患者在试验期间进展速度明显更快，但在开始TF治疗后速度减缓。接受TF治疗3年后，疾病进展速度与连续接受TF治疗5年的组相似。此外，新南威尔士州正在对470例临床确诊的MS患者进行TF开放研究治疗。通过神经学评估监测疾病进展速度，其似乎与最初试验中接受TF治疗的患者相似。对1980年TF试验患者的随访研究以及对470例MS患者的开放研究证实了最初的观察结果，即TF对减缓MS病程有一定作用。
